Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
1.585
+0.065 (4.28%)
At close: Jul 27, 2026, 4:00 PM EDT
1.640
+0.055 (3.47%)
Pre-market: Jul 28, 2026, 7:35 AM EDT

Aldeyra Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-28.38-35.27-60.12-42.79-62.68-56.22
Net Income
-27.37-33.85-55.85-37.54-62.02-57.78
Earnings Per Share
-0.45-0.56-0.94-0.64-1.06-1.07
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
6570.04101.15142.82174.3229.79
Total Debt
15.5115.5315.315.6616.0815.86
Net Cash (Debt)
49.4954.5185.85127.17158.22213.93
Net Cash Growth
-33.56%-36.50%-32.49%-19.63%-26.04%242.12%
Net Cash Per Share
0.820.911.442.162.713.96

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-25.99-33.35-43.21-30.33-56.64-42.56
Capital Expenditures
-----0.02-0.01
Free Cash Flow
-25.99-33.35-43.21-30.33-56.65-42.56
Free Cash Flow Growth
------

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-16.3213.27---